Dainippon Pharmaceutical Company, Limited

The United States of America as Represented by the Secretary of

The United States of America as Represented by the Department of Health

Ryuji Furuta

Junichi Yamagishi

Kouji Matsushima

Masaaki Yamada

Hitoshi Kawashima

Hirotada Kotani

Shinichi Nakamura

Teizo Yoshimura

Yoshiyuki Takase

Shigeo Kawata

Shunsuke Naruto

Michiko Yamayoshi

Akira Minami

Katuhisa Nakata

Toshikazu Fukui

A simple and efficient method of preparing active recombinant human neutrophil chemotactic factor. The human neutrophil chemotactic factor (NCF) is solubilized from a transformant cell homogenate using urea or guanidine hydrochloride. The polypeptide is further purified from the solution using conventional protocols such as CM-Sepharose CL-6B, HW-55 column, etc.. By using this method, large amounts of active human NCF can be recovered and purified.

Method of preparing an active human neutrophil chemotactic factor

An expression vector in which a DNA encoding a human neutrophil chemotactic factor polypeptide is inserted, a transformant (a host cell transformed with the expression vector), and a process for production of the said polypeptide by using the said transformant.

Process for producing a human neutrophil chemotactic factor peptide and

Novel polypeptides having a modified amino acid sequence of human interleukin 1.alpha. polypeptides in which a certain amino acid residue(s) in said amino acid sequence is(are) exchanged for other amino acid residue(s). Said polypeptides having no capacity of induction of production of prostaglandin E.sub.2 while maintaining other biological activities of human interleukin 1 such as activation of lymphocyte and being expected to be useful as a medicament.

Modified polypeptides of IL-1.alpha.

A human TNF polypeptide mutant having an amino acid sequence of modified human TNF polypeptide, a DNA having a base sequence encoding the above human TNF polypeptide mutant and a method of producing the above human TNF polypeptide mutant by culturing a host transformed with a vector having inserted therein the above DNA. The above human TNF polypeptide mutant is soluble and has antitumor activity.

Novel human TNF polypeptide mutants and DNA's encoding said mutants

Novel glucosaminyl muramyl peptide derivatives of the formula: ##STR1## wherein X is hydrogen atom or a group of the formula: R.sub.1 CO--, Y is hydroxy group or a group of the formula: --OR.sub.2, ##STR2## R.sub.1 is an alkyl or alkenyl group, R.sub.2 is a lower alkyl group or a phenylalkyl group, R.sub.3 and R.sub.4 are the same or different and are each hydrogen atom or an alkyl group, Y' is hydroxy group or a group of the formula: --OR.sub.2 or ##STR3## (D) and (L) mean the configuration, provided that when X is hydrogen atom, Y is a group of the formula: ##STR4## and their pharmaceutically acceptable salts. They have excellent biological activities such as potentiating activity of nonspecific resistance to microbial infections and immunostimulant activity and hence are useful in the prophylaxis and treatment of various microbial infections.

Glucosaminyl muramyl peptide derivatives

Growing community of inventors

Ohtsu, Japan

Ryuji Furuta